Fadi Dahdaleh
Fadi Dahdaleh has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Kiran Kalyan Turaga
Division of Surgical Oncology, Yale School of Medicine, New Haven, USA
2 shared publications - Scott K. Sherman
Department of Surgery, University of Iowa Carver College of Medicine, Iowa City, Iowa
2 shared publications - Sivesh Kathir Kamarajah
University of Birmingham
2 shared publications Alaine Kamm
Department of Surgery, University of Chicago, Chicago, Illinois
1 shared publicationAndrew M. Millis
Department of Surgery, University of Chicago, Chicago, Illinois
1 shared publicationBlase N. Polite
The University of Chicago Medicine, Section of Medical Oncology, Chicago, IL
1 shared publication
Latest Publications
- Open Access
- 30 March 2021
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (11) , 6790-6802
Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study
Background: Data supporting the routine use of adjuvant chemotherapy (AC) compared with no AC (noAC) following neoadjuvant chemotherapy (NAC) and resection for pancreatic ductal adenocarcinoma (PDAC) are lacking. This study aimed to determine whether AC improves long-term survival in patients receiving NAC and resection. Methods: Patients receiving resection for PDAC following NAC from 2004 to 2016 were identified from the National Cancer Data Base (NCDB). Patients with a survival rate of < 6 months were excluded to account for immortal time bias. Propensity score matching (PSM) and Cox regression analysis were performed to account for selection bias and analyze the impact of AC on overall survival. Results: Of 4449 (68%) noAC patients and 2111 (32%) AC patients, 2016 noAC patients and 2016 AC patients remained after PSM. After matching, AC was associated with improved survival (median 29.4 vs. 24.9 months; p < 0.001), which remained after multivariable adjustment (HR 0.81, 95% confidence interval [CI] 0.75–0.88; p < 0.001). On multivariable interaction analyses, this benefit persisted irrespective of nodal status: N0 (hazard ratio [HR] 0.80, 95% CI 0.72–0.90; p < 0.001), N1 (HR 0.76, 95% CI 0.67–0.86; p < 0.001), R0 margin status (HR 0.82, 95% CI 0.75–0.89; p < 0.001), R1 margin status (HR 0.77, 95% CI 0.64–0.93; p = 0.007), no neoadjuvant radiotherapy (NART; HR 0.84, 95% CI 0.74–0.96; p = 0.009), and use of NART (HR 0.80, 95% CI 0.73–0.88; p < 0.001). Stratified analysis by nodal, margin, and NART status demonstrated consistent results. Conclusion: AC following NAC and resection is associated with improved survival, even in margin-negative and node-negative disease. These findings suggest completing planned systemic treatment should be considered in all resected PDACs previously treated with NAC.
- 30 March 2021
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (11) , 6790-6802
Open AccessAdjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study
Background: Data supporting the routine use of adjuvant chemotherapy (AC) compared with no AC (noAC) following neoadjuvant chemotherapy (NAC) and resection for pancreatic ductal adenocarcinoma (PDAC) are lacking. This study aimed to determine whether AC improves long-term survival in patients receiving NAC and resection. Methods: Patients receiving resection for PDAC following NAC from 2004 to 2016 were identified from the National Cancer Data Base (NCDB). Patients with a survival rate of < 6 months were excluded to account for immortal time bias. Propensity score matching (PSM) and Cox regression analysis were performed to account for selection bias and analyze the impact of AC on overall survival. Results: Of 4449 (68%) noAC patients and 2111 (32%) AC patients, 2016 noAC patients and 2016 AC patients remained after PSM. After matching, AC was associated with improved survival (median 29.4 vs. 24.9 months; p < 0.001), which remained after multivariable adjustment (HR 0.81, 95% confidence interval [CI] 0.75–0.88; p < 0.001). On multivariable interaction analyses, this benefit persisted irrespective of nodal status: N0 (hazard ratio [HR] 0.80, 95% CI 0.72–0.90; p < 0.001), N1 (HR 0.76, 95% CI 0.67–0.86; p < 0.001), R0 margin status (HR 0.82, 95% CI 0.75–0.89; p < 0.001), R1 margin status (HR 0.77, 95% CI 0.64–0.93; p = 0.007), no neoadjuvant radiotherapy (NART; HR 0.84, 95% CI 0.74–0.96; p = 0.009), and use of NART (HR 0.80, 95% CI 0.73–0.88; p < 0.001). Stratified analysis by nodal, margin, and NART status demonstrated consistent results. Conclusion: AC following NAC and resection is associated with improved survival, even in margin-negative and node-negative disease. These findings suggest completing planned systemic treatment should be considered in all resected PDACs previously treated with NAC.
- 2 January 2021
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (4) , 1906-1907
ASO Author Reflections: Is Neoadjuvant Chemotherapy Associated with Acceptable Short-Term Outcomes for Pancreatic Cancer?
- 2 January 2021
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (4) , 1906-1907
ASO Author Reflections: Is Neoadjuvant Chemotherapy Associated with Acceptable Short-Term Outcomes for Pancreatic Cancer?
- 19 August 2019
- Published by Wiley in Journal of Surgical Oncology
- Vol. 120 (6) , 1044-1045
Implementation of bundled care to reduce surgical site infections after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
- 19 August 2019
- Published by Wiley in Journal of Surgical Oncology
- Vol. 120 (6) , 1044-1045
Implementation of bundled care to reduce surgical site infections after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy